1
|
Chen Z, Yu F, Zhu B, Li Q, Yu Y, Zong F, Liu W, Zhang M, Wu S. Integrated analysis of competitive endogenous RNA networks in elder patients with non-small cell lung cancer. Medicine (Baltimore) 2023; 102:e33192. [PMID: 36897674 PMCID: PMC9997791 DOI: 10.1097/md.0000000000033192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 02/14/2023] [Indexed: 03/11/2023] Open
Abstract
BACKGROUND Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related deaths worldwide; non-small cell lung cancer (NSCLC) comprises approximately 80% of all lung cancer cases. This study aimed to construct a competing endogenous RNA (ceRNA) network and identify prognostic signatures in elderly patients with NSCLC. METHODS We extracted data from elderly patients with NSCLC from The Cancer Genome Atlas and identified differentially expressed (DE) messenger RNAs (mRNAs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to investigate the functions of DEmRNAs. The interactions between RNAs were predicted using starBase, TargetScan, miRTarBase, and miRanda. Cytoscape version 3.0 was used to construct and visualize the lncRNA-miRNA-mRNA ceRNA network. The association between the expression levels of DERNAs in the constructed ceRNA network and overall survival was determined using the survival package in R software. Furthermore, another Gene Expression Omnibus cohort was studied to externally validate the ceRNA network. RESULTS In total, 2865 DEmRNAs, 62 DEmiRNAs, and 131 DElncRNAs were identified. Dysregulated mRNAs are enriched in cancer-related processes and pathways. A ceRNA network was constructed using 38 miRNAs, 61 lncRNAs, and 164 mRNAs. Of these, 3 lncRNAs, 3 miRNAs, and 16 mRNAs were closely related to overall survival. The MIR99AHG-hsa-miR-31-5p-PRKCE axis has been identified as a potential ceRNA network involved in the development of NSCLC in elderly individuals. External validation of the MIR99AHG-hsa-miR-31-5p-PRKCE axis in the GSE19804 cohort showed that PRKCE was downregulated and that MIR99AHG was upregulated in the tumor tissues of elderly patients with NSCLC compared with normal lung tissues. CONCLUSIONS This study provides novel insights into the lncRNA-miRNA-mRNA ceRNA network and reveals potential biomarkers for the diagnosis and prognosis of elderly patients with NSCLC.
Collapse
Affiliation(s)
- Zi Chen
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Fei Yu
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Bei Zhu
- Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Qin Li
- Yale Cancer Center, Yale School of Medicine, New Haven, CT
| | - Yue Yu
- Departments of Thoracic Surgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Feng Zong
- Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Wen Liu
- Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Mingjiong Zhang
- Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Shuangshuang Wu
- Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
| |
Collapse
|
2
|
Liu D, Huang Y, Zhou Q, Liu L, Che G, Lu Y, Xu F, Luo F, Bai H, Li W. [Pulmonary Nodules/Lung Cancer Comprehensive Management Mode: Design and Application]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2020; 23:299-305. [PMID: 32279474 PMCID: PMC7260385 DOI: 10.3779/j.issn.1009-3419.2020.103.06] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
背景与目的 早期筛查是有效降低肺癌死亡率的重要方式, 然而我国尚缺乏统一、有效的肺癌早期筛查标准与手段。本研究基于四川大学华西医院构建的肺结节/肺癌患者全程管理平台, 将肺结节早期筛查纳入肺癌规范诊疗体系, 以期实现提升肺癌患者生存率。 方法 建立三大研究队列:健康人群筛查队列、肺结节患者队列、肺癌患者队列, 系统、持续收集、分析各队列人群临床诊疗相关大数据。初步计划对肺结节早期筛查效果进行验证。 结果 该平台初步以2015年1月1日-2019年12月31日华西医院40岁以上职工2, 836人作为实施对象, 共诊断66例肺癌, 均经外科手术切除确诊为早期肺癌65例, 1例肺癌伴脑转移。 结论 肺结节/肺癌患者全程管理项目可实现肺结节高效筛查、随访与诊疗, 未来全程管理模式将全面覆盖华西医疗系统, 发挥区域带动作用。
Collapse
Affiliation(s)
- Dan Liu
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Yan Huang
- Health Management Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Qinghua Zhou
- Department of Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Lunxu Liu
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Guowei Che
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
| | - You Lu
- Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Feng Xu
- Department of Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Feng Luo
- Department of Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Hongli Bai
- Department of radiology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Weimin Li
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
| |
Collapse
|
3
|
Wang Z, Han W, Zhang W, Xue F, Wang Y, Hu Y, Wang L, Zhou C, Huang Y, Zhao S, Song W, Sui X, Shi R, Jiang J. Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice. CHINESE JOURNAL OF CANCER 2017; 36:57. [PMID: 28709441 PMCID: PMC5512753 DOI: 10.1186/s40880-017-0221-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 01/16/2017] [Indexed: 12/18/2022]
Abstract
BACKGROUND Mortality outcomes in trials of low-dose computed tomography (CT) screening for lung cancer are inconsistent. This study aimed to evaluate whether CT screening in urban areas of China could reduce lung cancer mortality and to investigate the factors that associate with the screening effect. METHODS A decision tree model with three scenarios (low-dose CT screening, chest X-ray screening, and no screening) was developed to compare screening results in a simulated Chinese urban cohort (100,000 smokers aged 45-80 years). Data of participant characteristics were obtained from national registries and epidemiological surveys for estimating lung cancer prevalence. The selection of other tree variables such as sensitivities and specificities of low-dose CT and chest X-ray screening were based on literature research. Differences in lung cancer mortality (primary outcome), false diagnoses, and deaths due to false diagnosis were calculated. Sensitivity analyses were performed to identify the factors that associate with the screening results and to ascertain worst and optimal screening effects considering possible ranges of the variables. RESULTS Among the 100,000 subjects, there were 448, 541, and 591 lung cancer deaths in the low-dose CT, chest X-ray, and no screening scenarios, respectively (17.2% reduction in low-dose CT screening over chest X-ray screening and 24.2% over no screening). The costs of the two screening scenarios were 9387 and 2497 false diagnoses and 7 and 2 deaths due to false diagnosis among the 100,000 persons, respectively. The factors that most influenced death reduction with low-dose CT screening over no screening were lung cancer prevalence in the screened cohort, low-dose CT sensitivity, and proportion of early-stage cancers among low-dose CT detected lung cancers. Considering all possibilities, reduction in deaths (relative numbers) with low-dose CT screening in the worst and optimal cases were 16 (5.4%) and 288 (40.2%) over no screening, respectively. CONCLUSIONS In terms of mortality outcomes, our findings favor conducting low-dose CT screening in urban China. However, approaches to reducing false diagnoses and optimizing important screening conditions such as enrollment criteria for screening are highly needed.
Collapse
Affiliation(s)
- Zixing Wang
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| | - Wei Han
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| | - Weiwei Zhang
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| | - Fang Xue
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| | - Yuyan Wang
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| | - Yaoda Hu
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| | - Lei Wang
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| | - Chunwu Zhou
- Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021 P. R. China
| | - Yao Huang
- Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021 P. R. China
| | - Shijun Zhao
- Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021 P. R. China
| | - Wei Song
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 P. R. China
| | - Xin Sui
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730 P. R. China
| | - Ruihong Shi
- National Institutes for Food and Drug Control, State Food and Drug Administration, Beijing, 100050 P. R. China
| | - Jingmei Jiang
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, 100005 P. R. China
| |
Collapse
|